Your SlideShare is downloading. ×
Barclays Capital 2011 Global Healthcare Conference
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Barclays Capital 2011 Global Healthcare Conference

3,023
views

Published on

Pfizer Worldwide Research & Development …

Pfizer Worldwide Research & Development
Presentation by Mikael Dolsten, M.D., PhD.
Barclays Capital 2011 Global Healthcare Conference
March 17, 2011

Published in: Investor Relations

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
3,023
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
47
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pfizer Worldwide Research & DevelopmentPresentation by Mikael Dolsten, M.D., PhD.Barclays Capital 2011 Global Healthcare ConferenceMarch 17, 2011
  • 2. Forward-Looking Statements Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2010 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K. These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section. 1
  • 3. Pfizer R&D: Important Progress 2009-2011 A Strengthened R&D Organization Centered on pipeline delivery Applying a breadth of science and technology Improving decision-making and clinical development of candidates Delivering smarter, more authentic integration of science and business Establishing a new standard for engagement of world class scientific talent Driving a vibrant culture of science 2
  • 4. A Comprehensive Turn-AroundStrategy is Underway Focused on Three Horizons to Drive Sustained Progress Precision Medicine Horizon 3 Networked, interactive R&D R&D Ecosystem of the Future Breakthrough productivity Next generation therapeutics Horizon 2 Open and external innovation Innovate New Capabilities Vaccines for all ages and geographies Maximize productivity and ROI Horizon 1 Deep knowledge of pathogenic mechanisms Deliver the Portfolio Medically differentiated products 3
  • 5. Recent Moves to Accelerate Our Progress Creating an 1 engine for Creating greater Improving output and focus to strengthen our sustainable reducing costs to innovation scientific core drive productivity 2 Probability Quality of Driving competitive of Success Output advantage through strategic externalization Cost per Speed Product 3 Positioning ourselves for differentiated innovation 4
  • 6. ___________________________________ DELIVER THE PORTFOLIO Today’s Key Registration Assets …and Potential Key Near-Term Submissions In Registration Near Term Filing OpportunitiesPrevenar 13 Adult (Pneumococcal Disease) Apixaban (Atrial Fibrillation) Axitinib (Renal Cell Carcinoma)Pristiq (Vasomotor Symptoms of Menopause) Bosutinib (Chronic Myelogenous Leukemia)Xiapex (Dupuytrens Contracture ) Crizotinib (Non-Small Cell Lung Cancer)*Tafamidis meglumine (transthyretinamyloidosis polyneuropathy) Tofacitinib (formerly Tasocitinib, Rheumatoid Arthritis) Xiapex recently approved in the EU * Crizotinib rolling submission underway in the U.S. 5
  • 7. Today’s Rich Phase 3 Portfolio Bapineuzumab – Alzheimer’s Disease Tofacitinib – Rheumatoid Bazedoxifene-conjugated estrogens Arthritis (Aprela) – Menopausal Vasomotor Zithromax / chloro – Malaria Symptoms Tanezumab – OA Pain (on 13 Axitinib – Renal Cell Carcinoma clinical hold) NMEs Crizotinib – Lung Cancer Bosutinib – Chronic Moxidectin – River Blindness Myelogenous Leukemia Inotuzumab – Aggressive Non-Hodgkin’s Neratinib – Breast Cancer Lymphoma PF-299804 – Lung Cancer Dimebon – Alzheimer’s Disease Apixaban – Atrial Fibrillation Several Apixaban – VTE Treatment New Tofacitinib – Psoriasis (Oral)Indications Dimebon – Huntington’s Disease Xiapex – Peyronie’s Disease 6
  • 8. Early to Mid-Stage Pipeline Shapes the FutureImmunology & • Strong pipeline of anti-inflammatory drugs across multiple disease areas Inflammation – e.g., anti-IL21 receptor, anti-madcam antibody and anti-TNF nanobody • Growing diabetes clinical pipeline CVMED – e.g., SGLT2 inhibitor, Glucokinase activators and four novel insulin sensitizing mechanisms • Robust oncology pipeline, applying Precision Medicine principles Oncology – e.g., PI3K-mTOR inhibitors, VEGF/Ang-2 inhibitor, ALK1 mAb and CDK4/6 inhibitors • Expanding pipeline of infectious disease vaccines Vaccines – e.g., Meningococcal group B for adolescents and S. aureus for hospital infections • Growing Neuroscience pipeline across disease areas and target classesNeuroscience – e.g., drugs targeting 5HT6, mAb to Amyloid, PDE10 and α4β2 7
  • 9. ________________________________________ INNOVATE NEW CAPABILITIES Next Generation Therapeutics: Inotuzumab Specific mAb-like target binding allows precise delivery to cancer cells Click to edit Master text styles LINKER Second level Calicheamicin Third level Calicheamicin CMC-544 Internalized Linker Hydrolized Released DS DNA Breaks Fourth level Apoptosis Intracellularly Fifth level• Inotuzumab ozogamicin is a potent anti-CD22 antibody-calicheamicin conjugate• Major B-cell malignancy currently under study: – Phase 2 study with Inotuzumab plus Rituximab in refractory Non-Hodgkin’s Lymphoma (NHL) demonstrated positive proof of concept, with strong efficacy and favorable tolerability – Phase 3 study started in patients with aggressive NHL tumors Over 10 pre-clinical Antibody Drug Conjugate (ADC) programs underway; first ADC against cancer stem cells expected to hit FIH within a year 8
  • 10. Pfizer’s Open Innovation Model: Centers for Therapeutic Innovation (CTI) Click to edit Master text styles Second level Third level Fourth level Fifth level NYC – East River Science Park Agreements signed with: • NYU Langone Medical Center UCSF • Rockefeller University HospitalUCSF agreement completed • Memorial Sloan-Kettering Cancer Center • Mount Sinai HospitalProgressing discussions with • Columbia University Medical Centerother highly regarded institutions • Albert Einstein College of Medicine • Weill Cornell Medical College 9
  • 11. ______________________________________________ R&D ECOSYSTEM OF THE FUTURE What is “Precision Medicine”? Click to edit Master Precision Medicine: Right Target, Right Drug(s), Right Patient text styles Second level Medicines targeting patient segments that Third level will have an optimal response to therapy Fourth levelBuilding diseaseunderstanding to Linking disease understanding Fifth levelidentify the right and clinicalpathways and targets outcomes Segmented, not personalized (5-20%+ patient subgroups, not individuals) 10
  • 12. Precision Medicine Expected to Drive ImprovedDrug Development and Commercial Advantage Click to edit Master text styles Second level Third level Fourth level Fifth level 11
  • 13. Examples of Precision Medicine Approaches by Pfizer Drug/Target: Click to edit Master text styles RN-316/PCSK9 Targeted Patients: Drug/Target: Second level Hypercholesteremic patients unresponsive to statins - many will be FH pts Drug/Target: PF-04991532 Crizotinib/Anaplastic Lymphoma Kinase Third level heterozygous for mutant LDLR Liver Glucokinase Targeted Patients: Targeted Patients: NSCLC patients with EML-4/ALK translocation Fourth level Type 2 diabetes patients who are contra-indicated for or non-tolerant of metformin Fifth level Drug/Target: Drug/Target: ATR-107/IL-21R PD-332991Cyclin-Dependent Kinase 4/6 Targeted Patients: Patients with autoimmunes Targeted Patients: diseases that over-express Luminal-B Breast Cancer IL-21(Cyclin D amplified, p16-, Rb+) Drug/Target: Inotuzumab/CD-22 Targeted Patients: CD-22+ Hematological malignancies 12
  • 14. Q&A